Arrowhead Pharmaceuticals Inc ARWR:NASDAQ

Last Price$67.50NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$66.51 (2)
Ask (Size)$69.00 (5)
Day Low / HighN/A - N/A
Volume715.7 K
 

View Biotechnology IndustryPeer Comparison as of 12/03/2021

 

Arrowhead Pharmaceuticals Inc ( NASDAQ )

Price: $67.50
Change: -2.19 (3.14%)
Volume: 715.7 K
4:00PM ET 12/03/2021
 
 

Sarepta Therapeutics Inc ( NASDAQ )

Price: $78.50
Change: -4.69 (5.64%)
Volume: 1.7 M
4:00PM ET 12/03/2021
 
 

Mirati Therapeutics Inc ( NASDAQ )

Price: $132.35
Change: -4.71 (3.44%)
Volume: 638.8 K
4:00PM ET 12/03/2021
 
 

Intellia Therapeutics Inc ( NASDAQ )

Price: $101.03
Change: -8.92 (8.11%)
Volume: 979.1 K
4:00PM ET 12/03/2021
 
 

Neurocrine Biosciences Inc ( NASDAQ )

Price: $79.68
Change: -0.96 (1.19%)
Volume: 971.5 K
4:00PM ET 12/03/2021
 

Read more news Recent News

Jefferies Adjusts Price Target on Arrowhead Pharmaceuticals to $103 From $100, Maintains Buy Rating
12:02PM ET 11/23/2021 MT Newswires

Arrowhead Pharmaceuticals (ARWR) has an average outperform rating and a price target range of $45 to $106, according to analysts polled by Capital IQ. (MT...

Baird Adjusts Price Target on Arrowhead Pharmaceuticals to $81 From $79, Maintains Neutral Rating
12:02PM ET 11/23/2021 MT Newswires

Arrowhead Pharmaceuticals (ARWR) has an average outperform rating and a price target range of $45 to $106, according to analysts polled by Capital IQ. (MT...

Goldman Sachs Adjusts Price Target on Arrowhead Pharmaceuticals to $90 From $88, Maintains Neutral Rating
12:02PM ET 11/23/2021 MT Newswires

Arrowhead Pharmaceuticals (ARWR) has an average outperform rating and a price target range of $45 to $106, according to analysts polled by Capital IQ. (MT...

--SVB Leerink Adjusts Arrowhead Pharmaceuticals' Price Target to $45 from $44, Keeps Market Perform Rating
11:51AM ET 11/23/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionArrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA. View company web site for more details
Address177 East Colorado Boulevard
Pasadena, California 91105
Phone+1.626.304.3400
Number of Employees116
Recent SEC Filing11/22/20214
President, Chief Executive Officer & DirectorChristopher Richard Anzalone
Chief Financial OfficerKenneth Allen Myszkowski
Chief Medical OfficerJavier San Martin
Vice President-Information Technology & SystemsJeff Ketelhut

Company Highlights

Price Open$70.17
Previous Close$69.69
52 Week Range$57.92 - 93.66
Market Capitalization$7.0 B
Shares Outstanding104.3 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.22
Beta vs. S&P 500N/A
Revenue$16.1 M
Net Profit Margin-116.97%
Return on Equity-28.00%

Analyst Ratings as of 11/26/2021

Buy
7
Overweight
0
Hold
3
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset